Articles From: IGATE Closes Strong 2014; Revenues up 10.2% Year-over-Year to IGT and Wheel of Fortune® Ring in Jackpot-Studded New Year With More Than $2.7 Million in Wins


2015/1/20
IGATE Corporation (“IGATE” or the “Company”) (NASDAQ: IGTE), the New Jersey-headquartered integrated technology and operations solutions provider, today announced its financial results for the fourth quarter and full year ended December 31, 2014.
Sign-up for IGATE Closes Strong 2014; Revenues up 10.2% Year-over-Year investment picks
2015/1/6
IGATE, the integrated technology and operations company, has scheduled its Earnings Conference Call on Tuesday, January 20, 2015 to discuss the results of its fourth quarter ended December 31, 2014.
Sign-up for IGATE to Discuss Fourth Quarter Financial Results on January 20, 2015 investment picks
2015/2/19
http://www.marketwire.com/library/MwGo/2015/2/19/11G033564/IGEX_logo-1229964304974.jpg JAKARTA, INDONESIA--(Marketwired - February 19, 2015) - International Global Exchange (OTC PINK: IGEX) (the "Company") announced today it has filed its Form 10-K for the fiscal year ended July 31, 2014 and its Form 10-Q for the period ending October 31, 2014.
Sign-up for IGEX Corporate Business Update investment picks
2014/12/17
BUENA, N.J. , Dec.
Sign-up for IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 investment picks
2014/12/11
BUENA, N.J. , Dec.
Sign-up for IGI Laboratories Announces Pricing of $125 Million of 3.75% Convertible Senior Notes Due 2019 investment picks
2014/12/9
BUENA, N.J. , Dec.
Sign-up for IGI Laboratories Announces Proposed Offering of $125 Million of Convertible Senior Notes Due 2019 investment picks
2015/2/6
BUENA, N.J. , Feb.
Sign-up for IGI Laboratories To Hold Conference Call For 4th Quarter 2014 Results investment picks
2014/12/10
BUENA, N.J. , Dec.
Sign-up for IGI Laboratories To Present At 25TH Annual Oppenheimer Healthcare Conference On December 11, 2014 investment picks
2015/1/8
BUENA, N.J. , Jan.
Sign-up for IGI Laboratories To Present At 33rd Annual J.P. Morgan Healthcare Conference On January 15, 2015 investment picks
2014/12/2
BUENA, N.J. , Dec.
Sign-up for IGI Laboratories To Present At Piper Jaffray 26th Annual Healthcare Conference On December 2, 2014 investment picks
2014/12/1
IGI Now Has Nineteen Applications Pending at the FDA BUENA, N.J. , Dec.
Sign-up for IGI Laboratories, Inc. Announces 8th ANDA Submission Of 2014 investment picks
2014/12/23
IGI Filed Eleven ANDAs in 2014, and IGI Now Has Twenty-Two Applications Pending at the FDA BUENA, N.J. , Dec.
Sign-up for IGI Laboratories, Inc. Announces Three Additional ANDA Submissions investment picks
2015/1/5
http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Announces December 2014 Mutual Fund Sales and Total Assets Under Management investment picks
2015/2/3
http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Announces January 2015 Mutual Fund Sales and Total Assets Under Management investment picks
2014/12/2
http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Announces November 2014 Mutual Fund Sales and Total Assets Under Management investment picks
2014/12/10
http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Named to CDP's 2014 Canada Climate Disclosure Leadership Index investment picks
2015/2/13
http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. Reports Fourth Quarter and 2014 Earnings investment picks
2015/1/13
http://www.ccnmatthews.com/logos/20050803-IGMfinancial.jpg WINNIPEG, MANITOBA --
Sign-up for IGM Financial Inc. to Release Fourth Quarter 2014 Results investment picks
2014/12/5
By Shawn Langlois, MarketWatch Critical intelligence before the U.S. market opens At one point late Thursday, the two most popular stories on MarketWatch were in direct conflict.
Sign-up for Ignore copper and mind the Swiss as jobs bring focus back to the U.S. investment picks
2014/12/15
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it has entered into an amendment to its license agreement with Nerviano Medical Sciences, S.r.l. relating to its entrectinib (formerly RXDX-101) product candidate.
Sign-up for Ignyta Announces Amendment to License Agreement with Nerviano investment picks
2014/12/2
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification.
Sign-up for Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory investment picks
2015/2/2
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Pratik S.
Sign-up for Ignyta Expands Clinical Leadership Team with Appointments of Pratik Multani, M.D., M.S., as Chief Medical Officer and Adrian Senderowicz, M.D., as Clinical and Regulatory Strategy Officer investment picks
2014/12/9
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “entrectinib” for the company’s lead product candidate, RXDX-101.
Sign-up for Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101 investment picks
2014/12/29
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for Ignyta’s lead product candidate entrectinib for the treatment of neuroblastoma.
Sign-up for Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma investment picks
2015/2/17
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta’s lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.
Sign-up for Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer investment picks
2015/2/5
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta’s lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). “Entrectinib has the potential to address unmet needs of patients with rare cancers, and we will continue to aggressively pursue our clinical development program for entrectinib in solid tumors for the benefit of these patients,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
Sign-up for Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Non-Small Cell Lung Cancer investment picks
2015/1/6
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., and its Chief Scientific Officer and Senior Vice President, Research, Robert Wild, Ph.D., have been invited to participate in panel discussions relating to trends and innovation in the life sciences industry at the 2015 East/West CEO Conference on January 11, 2015 in San Francisco, CA.
Sign-up for Ignyta to Participate in Life Sciences Panel Discussions with Other Thought Leaders at the 2015 East/West CEO Conference investment picks
2015/2/4
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jonathan Lim, M.D., its President and Chief Executive Officer, and Jacob Chacko, M.D., its Chief Financial Officer, will be making a company presentation at the 2015 Leerink Global Healthcare Conference on February 11, 2015 at 8:25 a.m. Eastern time (5:25 a.m. Pacific time) in New York, NY.
Sign-up for Ignyta to Present at 2015 Leerink Global Healthcare Conference investment picks
2015/1/12
LAS VEGAS , Jan.
Sign-up for IGT and Wheel of Fortune® Ring in Jackpot-Studded New Year With More Than $2.7 Million in Wins investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: IGATE Closes Strong 2014; Revenues up 10.2% Year-over-Year to IGT and Wheel of Fortune® Ring in Jackpot-Studded New Year With More Than $2.7 Million in Wins
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent